使用GLP-1激动剂后向美国食品药品监督管理局报告的不良皮肤事件的横断面分析 - Suppr | 超能文献

Cross-Sectional Analysis of Adverse Dermatologic Events Reported to the FDA After Use of GLP-1 Agonists.

作者信息

Ituarte Bianca E, Taylor Mitchell A, Thomas Sierra I, Sharma Divya, High Robin, Wysong Ashley, Wei Erin X

出版信息

J Drugs Dermatol. 2024 Sep 1;23(9):e181-e182.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Cross-Sectional Analysis of Adverse Dermatologic Events Reported to the FDA After Use of GLP-1 Agonists.使用GLP-1激动剂后向美国食品药品监督管理局报告的不良皮肤事件的横断面分析

J Drugs Dermatol. 2024 Sep 1;23(9):e181-e182.

2

Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.不同 GLP-1 受体激动剂与胃肠道不良反应的关联性：基于 FDA 不良事件报告系统数据库的真实世界药物不良反应比例性研究。

Front Endocrinol (Lausanne). 2022 Dec 7;13:1043789. doi: 10.3389/fendo.2022.1043789. eCollection 2022.

3

Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.胰高血糖素样肽-1受体激动剂在2型糖尿病治疗中的疗效与安全性：一项系统评价和混合治疗比较分析

Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17.

4

Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.接受胰高血糖素样肽-1 受体激动剂治疗的 2 型糖尿病患者的治疗模式：与每周一次的艾塞那肽和利拉鲁肽相比，度拉糖肽具有更高的依从性和持久性。

Diabetes Obes Metab. 2017 Jul;19(7):953-961. doi: 10.1111/dom.12902. Epub 2017 Mar 16.

5

Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature.与 GLP-1 激动剂相关的罕见皮肤不良反应：文献复习。

Arch Dermatol Res. 2024 May 25;316(6):248. doi: 10.1007/s00403-024-02969-3.

6

The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).胰高血糖素样肽-1受体激动剂（GLP-1 RAs）与自杀倾向之间的关联：向美国食品药品监督管理局不良事件报告系统（FAERS）提交的报告

Expert Opin Drug Saf. 2024 Jan;23(1):47-55. doi: 10.1080/14740338.2023.2295397. Epub 2023 Dec 19.

7

Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.长效胰高血糖素样肽-1 受体激动剂与艾塞那肽每日 2 次和西格列汀在 2 型糖尿病中的疗效和安全性比较：系统评价和荟萃分析。

Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5.

8

Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.亚洲亚群可能从长效胰高血糖素样肽 1 受体激动剂中获得更大的心血管获益：心血管结局试验的荟萃分析。

Diabetes Metab J. 2019 Aug;43(4):410-421. doi: 10.4093/dmj.2018.0070. Epub 2018 Dec 27.

9

Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes.每周一次胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病患者 6 个月的血糖控制和体重结局的比较效果。

Diabetes Obes Metab. 2018 Feb;20(2):468-473. doi: 10.1111/dom.13107. Epub 2017 Oct 8.

10

Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.美国2型糖尿病患者胰高血糖素样肽-1受体激动剂治疗依从性的回顾性研究

Adv Ther. 2014 Nov;31(11):1119-33. doi: 10.1007/s12325-014-0166-0. Epub 2014 Nov 19.